

In this issue of *The Journal*, McKee et al. (1) present evidence that the binding of low molecular weight fragments of hyaluronan (HA) to alveolar macrophages via CD44 elicits the expression of a number of pro-inflammatory chemokines. These observations extend earlier findings reported by this group showing that HA fragments are capable of activating NF- $\kappa$ B (2) and induce the expression of insulin-like growth factor-1 by murine macrophages (3). These studies bring together two disparate and previously unconnected observations regarding the expression and biological activity of HA fragments. The first observation is that HA fragments are present at abnormally high levels in the joints of patients with rheumatoid arthritis (RA) and in other inflammatory conditions (4, 5). These HA fragments are thought to arise primarily as a result of activated leukocyte driven extracellular matrix degradation at sites of inflammation and their presence has been proposed as a biological marker of disease. The second observation is that HA fragments but not HA polymers have angiogenic activity, a process which has been proposed to play a key role in the maintenance and progression of RA and other chronic inflammatory diseases (6). The findings by Nobel and his colleagues suggest that the high levels of HA fragments found in inflamed tissues bind to leukocytes and other CD44 expressing cells and trigger a cascade of signaling events which are involved in maintaining and/or amplifying the inflammatory response. It is of interest to note that the biological activities elicited by the HA fragments are distinct from those elicited by the HA polymers. While HA polymers are components of extracellular matrix and a substrate for CD44 mediated cell adhesion, HA fragments are signaling molecules which alert the immune system that significant tissue damage has occurred at a site of inflammation.

The role of CD44 as a hyaluronan receptor (7–9) has been known for many years and is consistent with the hypothesis that CD44 is a cell adhesion molecule (10). In recent years many studies designed to explore the role of CD44 as a cell adhesion receptor have given rise to a large body of data demonstrating that this is a major function of CD44. For example, the results of two recent studies provide evidence that CD44-HA interactions mediate the binding of lymphocytes to cultured endothelial cells (11) and tonsillar stromal cells (12). These findings indicate that CD44 significantly contributes to the recruitment of leukocytes to sites of inflammation and to their migration through lymphatic tissues. However, although it is clear that CD44 functions as a cell adhesion molecule, there is also substantial evidence that CD44 is a potent signaling receptor. Early studies using anti-CD44 mAb to trigger the receptor in lieu of a physiological ligand established that CD44 is a costimulatory molecule on T cells (13–17). It is now known that similar effects can be triggered through CD44 following HA binding (9, 18, 19). The findings reported in this issue of *The Journal* by McKee et al. (1) add to our understanding of CD44

as a signaling receptor and further support the notion that the function of CD44 as a signaling molecule is as important as its function as a cell adhesion receptor (14, 20).

Recently, three groups have reported that anti-CD44 mAb have potent anti-inflammatory activity in vivo. Administration of an anti-CD44 mAb (IM7) was found to prevent cutaneous delayed-type hypersensitivity (DTH) responses (21). This same anti-CD44 mAb was found to prevent the progression of ongoing collagen induced arthritis, blocking leukocyte infiltration and tissue swelling (22, 23). In these two studies the investigators reported that the anti-CD44 mAb mediated the rapid release of CD44 from the surface of CD44 positive leukocytes presumably preventing the CD44-HA mediated recruitment of leukocytes. The findings by McKee et al. (1) and those reported by others on the role of CD44 as a signaling molecule suggest that the potent anti-inflammatory effects resulting from the mAb mediated shedding of CD44 from leukocytes may prevent not only leukocyte recruitment but also prevent their activation. This dual effect might account for the potent anti-inflammatory activity of this anti-CD44 mAb in vivo.

It is not possible to review in this short format the full complexity of the CD44 antigen: its multiple isoforms, its multiple ligands, and its varied and complex biological activities. The report of McKee et al. raises new and interesting questions regarding the function of CD44. For example, are all CD44 isoforms capable of binding HA fragments? Does the interaction between CD44 and HA fragments in other cell types lead to a signaling event? In particular, are the previously reported angiogenic properties of HA fragment mediated by CD44 molecules expressed on vascular endothelial cells? Is the ability of CD44 to bind HA fragments regulated in the same way as the interaction between CD44 and the HA polymer? Clearly, the recent findings by Nobel and his colleagues remind us that much remains to be learned about the function of the CD44 antigen and one of its ligands, HA.

A. Aruffo

Bristol-Myers Squibb Pharmaceutical Research Institute

## References

1. McKee, C.M., M.B. Penno, M. Cowman, C. Bao, and P.W. Noble. 1996. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. *J. Clin. Invest.* 98:2403–2413.
2. Noble, P.W., C.M. McKee, M. Cowman, and H. Shin. 1996. Hyaluronan fragment activate an NF- $\kappa$ B/I- $\kappa$ B $\alpha$  autoregulatory loop in murine macrophages. *J. Exp. Med.* 183:2373–2378.
3. Noble, P.W., F.R. Lake, P.M. Henson, and D.W.H. Riches. 1993. Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor- $\alpha$ -dependent mechanism in murine macrophages. *J. Clin. Invest.* 91:2368–2377.
4. Björner, L., R. Lundgren, and R. Hallgren. 1989. Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. *Thorax*. 44:126–131.
5. Poole, A., and P. Dieppe. 1994. Biological markers in rheumatoid arthritis. *Semin. Arthritis Rheum.* 23S:17–31.
6. West, D.C., I.N. Hampson, F. Arnold, and S. Kumar. 1985. Angiogenesis induced by degradation products of hyaluronic acid. *Science (Wash. DC)*. 228:1324–1326.
7. Aruffo, A., I. Stamenkovic, M. Melnick, C.B. Underhill, and B. Seed. 1990. CD44 is the principal cell surface receptor for hyaluronate. *Cell*. 61(7):1303–1313.
8. Culty, M., K. Miyake, P. W. Kincade, E. Silorski, E.C. Butcher, and C. Underhill. 1990. The hyaluronate receptor is a member of the CD44 (H-CAM)

family of cell surface glycoproteins. *J. Cell Biol.* 111:2765–2774.

9. Miyake, K., C.B. Underhill, J. Lesley, and P.W. Kincade. 1990. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. *J. Exp. Med.* 172:69–75.

10. Jalkanen, S., R.F. Bargatze, J. de los Toyos, and E.C. Butcher. 1987. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85–95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. *J. Cell Biol.* 105:983–990.

11. DeGrendele, H.C., P. Estess, L.J. Picker, and M.H. Siegelman. 1996. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. *J. Exp. Med.* 183:1119–1130.

12. Clark, R.A., R. Alon, and T.A. Springer. 1996. CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma. *J. Cell Biol.* 134:1075–1087.

13. Huet, S., H. Groux, B. Caillou, H. Valentin, M. Prieur, and A. Bernard. 1989. CD44 contributes to T cell activation. *J. Immunol.* 143:798–801.

14. Shimizu, Y., G.A. Van Seventer, R. Siraganian, L. Wahl, and S. Shaw. 1989. Dual role of the CD44 molecule in T cell adhesion and activation. *J. Immunol.* 143:2457–2463.

15. Denning, S.M., P.T. Le, K.H. Singer, and B.F. Haynes. 1990. Antibodies against the CD44 p80, lymphocytes homing receptor molecule augment human peripheral blood T cell activation. *J. Immunol.* 144:7–15.

16. Rothman, B.L., M.L. Blue, K.A. Kelley, D. Wunderlich, D.V. Mierz,

and T.M. Aune. 1991. Human T cell activation by OKT3 is inhibited by a monoclonal antibody to CD44. *J. Immunol.* 147:2493–2499.

17. Pierres, A., C. Mawas, and D. Olive. 1992. A unique CD44 monoclonal antibody identifies a new T cell activation pathway. *Eur. J. Immunol.* 22:413–417.

18. Galandrini, R., E. Galluzzo, N. Albi, C.E. Grossi, and A. Velardi. 1994. Hyaluronate is costimulatory for human T cell effector functions and binds to CD44 on activated T cells. *J. Immunol.* 153:21–31.

19. Lesley, J., N. Howes, A. Perschl, and R. Hyman. 1994. Hyaluronan binding function of CD44 is transiently activated on T cells during an in vivo immune response. *J. Exp. Med.* 180:383–387.

20. Haynes, B.F., M.J. Telen, L.P. Hale, and S.M. Denning. 1989. CD44 - A molecule involved in leukocyte adherence and T-cell activation. *Immunol. Today.* 10(12):423–428.

21. Camp, R.L., A. Scheynius, C. Johansson, and E. Puré. 1993. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. *J. Exp. Med.* 178:497–507.

22. Verdregh, M., R. Holmdahl, and A. Tarkowski. 1995. Administration of antibodies to hyaluronan receptor (CD44) delays the start and ameliorates the severity of collagen II arthritis. *Scand. J. Immunol.* 42:353–358.

23. Mikecz, K., F.R. Brennan, J.H. Kim, and T.T. Glant. 1995. Anti-CD44 treatment arogates tissue oedema and leukocyte infiltration in murine arthritis. *Nat. Med.* 1:558–563.